Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall
Director Robert I. Kauffman of Hagerty, Inc. (NYSE:HGTY), the $4.1 billion market cap company that has delivered an impressive 32.6% return over the past six months, sold a total of 54,065 shares of Class A Common Stock in a series of transactions between September 29 and October 1, 2025. The sales, executed under a Rule 10b5-1 trading plan, generated approximately $647,408.
The transactions occurred at weighted average prices ranging from $11.77 to $12.06 per share. Specifically, on September 29, 5,506 shares were sold at an average price of $11.77. On September 30, 30,187 shares were sold at an average price of $11.96. On October 1, 18,372 shares were sold at an average price of $12.06. The stock has shown strong momentum, gaining nearly 25% year-to-date.
Following these transactions, Kauffman, through Aldel LLC, continues to indirectly hold 1,132,877 shares of Hagerty , Inc. Class A Common Stock. Kauffman also directly holds 67,302 shares. According to InvestingPro analysis, the stock currently appears undervalued, with multiple growth indicators and financial health metrics available in the comprehensive Pro Research Report.
In other recent news, Hagerty Inc. reported its second-quarter earnings for 2025, showing a mixed performance. The company posted earnings per share of $0.09, which fell short of the forecasted $0.11. However, Hagerty exceeded revenue expectations with $369 million, surpassing the anticipated $293.87 million, resulting in a 25.46% revenue surprise. Additionally, Hagerty announced a secondary offering of 8.7 million shares of its Class A Common Stock, with the selling stockholders being Hagerty Holding Corp. and Aldel LLC. The company stated it would not receive any proceeds from this sale. In analyst updates, JMP Securities initiated coverage of Hagerty with a Market Outperform rating and a $15.00 price target. Oppenheimer also rated Hagerty as Outperform, setting a similar price target of $15.00. Meanwhile, BMO Capital initiated coverage with a Market Perform rating and a $13.00 price target. These developments provide investors with recent insights into Hagerty’s financial and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.